Malaria-Update on Antimalarial Resistance and Treatment Approaches. by Yeung, Shunmay
Yeung, S (2018) Malaria - Update on Antimalarial Resistance and
Treatment Approaches. The Pediatric infectious disease journal. ISSN
0891-3668 DOI: https://doi.org/10.1097/INF.0000000000001887
Downloaded from: http://researchonline.lshtm.ac.uk/4646056/
DOI: 10.1097/INF.0000000000001887
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Malaria – update on antimalarial resistance and treatment approaches 
 
Author:  Shunmay Yeung PhD  
 
Affiliation: Clinical Research Department, London School of Hygiene and Tropical 
Medicine and St Mary’s Imperial College Hospital, London 
 
Corresponding address: 
Clinical Research Department,  
London School of Hygiene and Tropical Medicine 
Keppel Street 
London 
WC1E 7HT 
E-mail: Shunmay.yeung@lshtm.ac.uk 
Telephone:  +44 20 7927 2657 
 
Funding:  SY is supported by a grant from the UK Department for International 
Development for the Tracking Resistance to Artemisinins Collaboration 2 (TRAC2) 
research programme  
 
Conflicts of interest:  None 
 
Keywords:  Malaria, drug resistance, P. falciparum, Artemisinin-based combination 
therapy 
 
Abbreviated title:  Malaria – update on drug resistance and treatment  
 
Running head title: Malaria – drug resistance and treatment 
  
Introduction 
Malaria continues to be a major cause of childhood mortality and was responsible for an 
estimated 303,000 (165,000-450,000) deaths in children aged under 5 years in 2015. 
However, this represents a 60% reduction in mortality since 2000 1, one of biggest 
successes in terms of the Millennium Development Goals.  Central to this achievement 
was the widespread deployment of effective tools for prevention and treatment, 
including insecticide treated nets and Artemisinin-based Combination Therapies (ACTs). 
The recent emergence and spread of Plasmodium falciparum (Pf) parasites resistant to 
ACTs, and mosquitoes resistant to the pyrethroids, the most commonly used insecticide, 
threaten to reverse these gains, and the hopes of eliminating malaria.  This review 
provides an update on antimalarial resistance and approaches to treatment.  
 
Types of malaria 
Nearly all malaria related deaths are due to Pf, which is also the most drug-resistant of 
the five species of Plasmodium to infect humans, and is the main focus of this review.  P. 
vivax  (Pv) which has a wider geographical spread and can cause severe disease, is also 
becoming increasingly resistant to chloroquine, and was the subject of a recent PIDJ 
review 2.  Zoonotic infections with P. knowlesi, which usually infects long-tailed 
macaques, are increasingly recognised as an important cause of human malaria in parts 
of Southeast Asia, especially Malaysia where it is responsible for over 70% of malaria 
cases, of which 10% are severe.  It is most effectively treated with ACTs.  P. malariae and 
P. ovale remain sensitive to chloroquine, but can also be treated effectively with ACTs.  
Although the cost of ACTs used to be higher than other antimalarials, their cost has 
fallen significantly and a number of countries now have simplified treatment guidelines 
which recommend ACTs for all species of malaria.  
 
Advances in malaria diagnostics 
Previously microscopy was the mainstay for parasitological diagnosis. However, it 
requires skilled microscopists, functioning microscopes and a reliable supply of 
reagents.  Therefore antimalarials were often taken presumptively, without 
parasitological confirmation, giving rise to concerns of under-treatment of patients with 
malaria, and overuse of antimalarials in patients without, and the associated risks in 
terms of drug resistance.      
 
The advent of malaria rapid diagnostic tests (mRDTs) in the last 10 years have 
transformed the diagnostic landscape.  Quality-assured mRDTs are sensitive and specific, 
provide a result within 20 minutes, are affordable (~€0.50 per test) and easy to use.  
Tests detect either Histidine Rich Protein 2 (HRP2), which is a Pf-specific antigen, 
and/or the pan-species antigen Plasmodium Lactate Dehydrogenase and have a similar 
sensitivity to good microscopy. Over 200 million mRDTs were distributed by national 
malaria programmes in 2015, largely enabled by donor support.  Microscopy still has an 
important role, in terms of quantification of parasite density, staging and treatment 
follow-up.  Of note HRP2 tests can remain positive several weeks after treatment so are 
not useful for follow-up. Secondly, parasites with HRP2 deletions have been detected, 
allowing them to evade detection by mRDT. Although prevalence rates of up to 40% 
have been reported from the Amazonian basin in Peru, they are much rarer elsewhere 
and currently not thought to be a major cause of false negative results.    Although more 
sensitive diagnostics are available which are able to detect parasite densities more than 
10-fold lower then microscopy and standard mRDTs, their role is currently limited to 
research and surveillance. These include PCR, Loop-mediated isothermal amplification 
(LAMP) and “Ultra-sensitive” HRP2 mRDTs,  
 
Antimalarial treatment 
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Artemisinin-based combination therapies are the mainstay of treatment for Pf malaria.  
Artemisinin derivatives, or “Qinghaosu”, had been used to treat fever in China more than 
two thousand years ago and were re-discovered by Chinese scientists during the 
American-Vietnam war.  They act on a broader range of parasite blood stages than any 
other antimalarial and are the most rapid acting, reducing (sensitive) parasite loads by 
an order of 105  fold every 48 hours. For uncomplicated Pf, they should always be given 
in combination with another effective drug with a different mechanism of action, ideally 
as a fixed dose combination.  This is for two reasons: firstly, on their own they need to 
be taken for at least 7 days which is poorly adhered to, and secondly to minimise the 
development of parasite resistance.  The partner drugs currently used in ACTs include: 
lumefantrine, amodiaquine, piperaquine, mefloquine, pyronaridine and sulfadoxine-
pyrimethamine (SP). As described later, in the Greater Mekong Sub-region (GMS), 
parasite have developed resistance to all partner drugs. In Sub-Saharan Africa resistance 
to SP is widespread but the other partner drugs remain effective.   The use of SP should 
be avoided in individuals who have HIV/AIDS, and the use amodiaquine should also be 
avoided if they are being treated with efavirenz or zidovudine due to the risk of 
exacerbation of hepatotoxicity and neutropenia respectively 3.  
 
For severe malaria, initial treatment should be with intravenous artesunate for at least 
24 hours followed by a full course of oral ACT.  Children weighing < 20 kg should receive 
a higher dose of artesunate (3 mg/kg per dose) than larger children and adults (2.4 
mg/kg per dose) 3. The largest randomized clinical trials ever conducted on severe 
falciparum malaria showed a substantial reduction of mortality with parenteral 
artesunate compared with parenteral quinine.  It is also safer, better tolerated, easier to 
administer (including once per day administration), and cost-effective 4, 5.  Artesunate 
suppositories are also now available, enabling pre-referral administration to children 
with severe malaria in remote settings, a potentially life-saving innovation.  Quinine 
remains a useful second-line drug for severe malaria.  
 
Supportive and adjunct therapy 
Children with complicated malaria require close monitoring of vital signs, fluid balance, 
glucose, biochemical and haematological markers. These should be used to guide 
resuscitation with fluids, glucose, and blood, while avoiding rapid bolus infusions.  Co-
infection with bacteria is not uncommon and all children with severe malaria should 
also receive intravenous antibiotics, pending blood culture results. Haemofiltration 
should be considered early in children with renal dysfunction.   Although there is 
anecdotal experience of exchange transfusions, there is insufficient evidence to make 
any practical recommendations.  Similarly adjunctive therapies including immune 
modulators (high-dose corticosteroids, anti-TNF agents, cyclosporin, hyperimmune 
serum) and anticoagulants have been evaluated with varying results in terms of 
effectiveness and safety.  
 
Antimalarial resistance 
Treatment failure and parasite clearance times 
Clinically, drug resistance first manifests as the slower clearance of parasite from the 
blood stream and longer time for patients to defervesce 6, 7. As resistance worsens, less 
sensitive parasites survive and multiply resulting in recrudescent parasitaemia and  
treatment failure.   The interval between initial treatment to recrudescence depends on 
the level of resistance, patient immunity and the pharmacokinetic-pharmacodynamic 
relationship.  Drugs with long half-life such as mefloquine and piperaquine, continue to 
exert some inhibitory effect on partially resistant parasites for weeks, so infections may 
not recrudesce for several weeks.   For drugs with short half lives, and with parasites 
which are more resistant (and therefore able to grow in the presence of drugs), the 
interval to recrudescence can be a matter of days and in extreme cases there will be no 
initial clearance of parasites.   
 
It is worth noting that resistant parasites are not the only cause of recrudescent 
infections.   Recrudescence can occur due to sub-therapeutic dosing which in turn can be 
due to an inadequate dose being prescribed, poor patient adherence to a correctly 
prescribed regime, poor absorption (particularly for lumefantrine which needs to be 
taken with fatty food)– or poor quality drugs.   The latter is extremely common in 
malaria-endemic countries where studies have shown the prevalence of poor quality 
drugs (defined as <85% of stated active ingredient) to be as high as 31% 8.  In addition 
to recrudescence, recurrent infections can also be due re-infection or relapse which 
refers to the recurrence of blood-stage infections due activation of hypnozoites in P. 
vivax and P. ovale infections.  
 
Monitoring of antimalarial resistance 
In malaria-endemic countries routine monitoring of antimalarial drug efficacy is carried 
out at sentinel sites by national malaria control programmes using a standardised WHO 
protocol.  Treatment response is defined as the absence of parasitaemia at follow-up, on 
day 28 or 42.   WHO recommends that when a 10% treatment failure rate is reached, a 
switch to another more effective first-line drug is made 7.  
 
Genetic markers for most forms of antimalarial resistance have now been described and 
include specific mutations in the propeller domain of the Kelch13  gene associated with 
artemisinin resistance 9, and in the  plasmepsin 2-3 gene associated with piperaquine 
resistance 10.    Surveillance for resistance markers can be carried out by polymerase 
chain reaction (PCR) on dried blood spots collected on filter paper from a fingerprick.  
Genetic resistance testing is currently only used for research and surveillance  
(http://www.wwarn.org/), although rapid advances in diagnostics technology mean 
that it may soon be technically possible to undertake point-of-care diagnosis in a clinical 
setting.  In-vitro resistance, where cultured parasites are exposed to different 
concentrations of antimalarials, is restricted to highly specialised research laboratories.      
 
Resistance to artemisinins and partner drugs 
Artemisinin-resistant Pf was first documented on the Thai-Cambodian border in 2007-
2008 6, and is now found throughout most of the Great Mekong Sub-region (GMS) 
including in Vietnam, Myanmar and Laos 7, 11.   To date, although there are reports of 
ACT treatment failures elsewhere, artemisinin resistance has not yet been confirmed in 
Africa.   However, with modern travel patterns, there are concerns that the spread of 
artemisinin-resistance is likely to be much faster than that of chloroquine-resistance, 
which also first emerged on the Thai-Cambodia border in the 1950s, reaching the East 
coast of Africa in the 1980s.   If the spread of artemisinin resistance outpaces the speed 
at which a new class of antimalarials becomes available, the gains of the last 15 years 
will be lost and with it the hopes of eliminating malaria.  
 
The situation in the GMS has become critical.  Not only has resistance to the artemisinins 
spread geographically, but a specific resistant Kelch13 haplotype (ie C580Y) is now 
becoming fixed in the parasite population and the emergence of resistance to the key 
partners drugs has also been confirmed 7.    In Cambodia treatment failure rates of 
around 40% to the first-line combination of dihydroartemisinin-piperaquine 12 forced a 
switch back to the previous first-line combination of artesunate and mefloquine which 
had only been switched from 4 years previously due to high levels of resistance.   
Fortunately there is some laboratory evidence to suggest that parasites which are 
resistant to mefloquine remain relatively sensitive to piperaquine and vice versa.  The 
same phenomenon has also been observed between lumefantrine and amodiaquine, the 
two main partner drugs used in Africa, neither of which however are effective in the 
GMS.  Although this affords a little more buying time before a new class of antimalarials 
becomes available, the current pipeline will not bring a novel product to the market 
within the next 5 years (https://www.mmv.org/access/products-projects), and 
alternative approaches to deploy the current tools are being explored. This includes 
longer courses, the use of triple combinations containing artemisinin and two non-
artemisinin partner drugs either at the same time or sequentially.  
 
Treatment approaches in context of elimination 
Elimination of malaria has now become a global health strategy in a number of regions 
including in the GMS, partly in response to the threat of artemisinin-resistance.  
Where there is a public health goal of transmission reduction in addition to individual 
patient cure, additional therapeutic approaches may apply. Treatment of Pf with single 
low dose (0.25mg/kg) primaquine is advocated in addition to an ACT, in order to clear 
gametocytes, the sexual form which does not cause symptoms but is responsible for 
transmission.   The potential to exploit the mosquito killing properties of the anti-
helminthic drug ivermectin is also being explored.  At a population level, approaches to 
eliminate the malaria reservoir in asymptomatic carriers are being explored. These 
include mass drug administration and active screening and treatment using highly 
sensitive diagnostics aimed at detecting low-density infections. 
 
Conclusion 
The majority of malaria cases presenting to healthcare facilities in Europe are in people 
returning from visiting friends and relatives in Africa, where thankfully parasites remain 
sensitive to the artemisinins and the main partner drugs used in ACTs -  including 
artemether-lumefantrine, dihydroartemisinin-piperaquine, artesunate-pyronaridine, 
the three fixed dosed ACTs that currently have EMA approval. These ACTs are safe and 
effective against all types of malaria, not just P. falciparum malaria, making it possible to 
simplify treatment guidelines so that the first line treatment for uncomplicated malaria 
due to any species is an ACT, followed by primaquine for P. vivax or P. ovale, if not GP6D 
deficient. Quinine is still an effective drug and is a useful second line for severe malaria.  
Atovaqoune-proquanil (Malarone), which is primarily used for prophylaxis in travellers, 
also remains effective against Pf but its price and vulnerability to the development of 
resistance limits its use as a first-line agent in malaria-endemic countries. 
 
This review has focused on the antimalarial resistance and treatment approaches, but 
prevention is better than cure.  As health professionals we have a responsibility to 
ensure that patients receive risk-based pre-travel advice and where appropriate, 
effective antimalarial prophylaxis.  
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